On this page
tretinoin
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Retinoid [EPC] | EPC | All 35 members |
| Retinoids [CS] | CS | All 35 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 215713-001 | TRETINOIN | CREAM | TRETINOIN | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | January 5, 2023 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260331). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingIndications and Usage: Tretinoin gel and cream are indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.
Dosage and Administration
openFDA Drug LabelingDosage and Administration: Tretinoin gel or cream should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Gel: Excessive application results in “pilling” of the gel, which minimizes the likelihood of over application by the patient. Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment. Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. During the early weeks of therapy, an apparent exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy. Therapeutic results should be noticed after two to three weeks but more than six weeks of therapy may be required before definite beneficial effects are seen. Once the acne lesions have responded satisfactorily, it may be possible to maintain the improvement with less frequent applications, or other dosage forms. Patients treated with tretinoin preparations may use cosmetics, but the areas to be treated should be cleansed thoroughly before the medication is applied ( see Precautions ).
Contraindications
openFDA Drug LabelingContraindications: Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.
Warnings
openFDA Drug LabelingWARNINGS Keep out of reach of children. Keep tube tightly closed. Do not expose to heat. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between l5°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin cream. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin cream. To date, all adverse effects of tretinoin cream have been reversible upon discontinuance of therapy (see Dosage and Administration). To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
openFDA Drug LabelingDrug Interactions Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin cream. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin cream is begun.
Description
openFDA Drug LabelingDescription: Tretinoin Gel, USP and Tretinoin Cream, USP are used for the topical treatment of acne vulgaris. Each gram of tretinoin gel contains tretinoin in either of two strengths, 0.025% (0.25 mg) or 0.01% (0.1 mg) in a gel vehicle of hydroxypropyl cellulose, butylated hydroxytoluene, and alcohol 90% w/w. Each gram of tretinoin cream contains tretinoin in either of three strengths, 0.1% (1 mg), 0.05% (0.5 mg), or 0.025% (0.25 mg) in a hydrophilic cream vehicle of: stearic acid, isopropyl myristate, polyoxyl 40 stearate, stearyl alcohol, xanthan gum, sorbic acid, butylated hydroxytoluene, and purified water. Chemically, tretinoin is all-trans -retinoic acid. It has a molecular weight of 300.44 and has the following structural formula: chemical-structure-tretinoin.jpg
Overdosage
openFDA Drug LabelingOverdosage: If medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling, or discomfort may occur. Oral ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A.
How Supplied / Storage and Handling
openFDA Drug LabelingHow Supplied Tretinoin is supplied as: Tretinoin Cream NDC Code Strength/Form Qty 0378-8082-20 0378-8082-45 0.025% Cream 0.025% Cream 20 g 45 g 0378-8083-20 0378-8083-45 0.05% Cream 0.05% Cream 20 g 45 g 0378-8084-20 0378-8084-45 0.1% Cream 0.1% Cream 20 g 45 g Tretinoin Gel NDC Code Strength/Form Qty 0378-8085-15 0378-8085-45 0.01% Gel 0.01% Gel 15 g 45 g 0378-8086-15 0378-8086-45 0.025% Gel 0.025% Gel 15 g 45 g Storage Conditions: Tretinoin Gel, 0.025% and 0.01%: store below 86°F. Tretinoin Cream, 0.1%, 0.05%, and 0.025%: store below 80°F. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Bausch Health Companies Inc. Laval, Quebec H7L 4A8, Canada Revised: 02/2024 VAL:TRETCG:R2 9631002
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: TRETINOIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-0651-0 | 50090-0651 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-0651-0) / 20 g in 1 TUBE | November 28, 2014 |
| 50090-3058-0 | 50090-3058 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-3058-0) / 45 g in 1 TUBE | June 15, 2017 |
| 50090-3128-0 | 50090-3128 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-3128-0) / 20 g in 1 TUBE | August 29, 2017 |
| 50090-4347-0 | 50090-4347 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-4347-0) / 45 g in 1 TUBE | June 11, 2019 |
| 50090-6819-0 | 50090-6819 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-6819-0) / 45 g in 1 TUBE | November 14, 2023 |
| 50090-7171-0 | 50090-7171 | A-S Medication Solutions | 1 TUBE in 1 CARTON (50090-7171-0) / 20 g in 1 TUBE | May 20, 2024 |
| 0472-0117-20 | 0472-0117 | Actavis Pharma, Inc. | 1 TUBE in 1 CARTON (0472-0117-20) / 20 g in 1 TUBE | April 20, 1998 |
| 0472-0117-45 | 0472-0117 | Actavis Pharma, Inc. | 1 TUBE in 1 CARTON (0472-0117-45) / 45 g in 1 TUBE | April 20, 1998 |
| 62332-807-20 | 62332-807 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-807-20) / 20 g in 1 TUBE | May 1, 2024 |
| 62332-807-45 | 62332-807 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-807-45) / 45 g in 1 TUBE | May 1, 2024 |
| 62332-808-20 | 62332-808 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-808-20) / 20 g in 1 TUBE | June 11, 2026 |
| 62332-808-45 | 62332-808 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-808-45) / 45 g in 1 TUBE | June 11, 2026 |
| 62332-809-20 | 62332-809 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-809-20) / 20 g in 1 TUBE | August 16, 2025 |
| 62332-809-45 | 62332-809 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-809-45) / 45 g in 1 TUBE | August 16, 2025 |
| 46708-807-20 | 46708-807 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-807-20) / 20 g in 1 TUBE | April 25, 2025 |
| 46708-807-45 | 46708-807 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-807-45) / 45 g in 1 TUBE | April 25, 2025 |
| 46708-808-00 | 46708-808 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-808-00) / 45 g in 1 TUBE | June 11, 2026 |
| 46708-808-20 | 46708-808 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-808-20) / 20 g in 1 TUBE | June 11, 2026 |
| 46708-809-20 | 46708-809 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-809-20) / 20 g in 1 TUBE | August 16, 2025 |
| 46708-809-45 | 46708-809 | Alembic Pharmaceuticals Limited | 1 TUBE in 1 CARTON (46708-809-45) / 45 g in 1 TUBE | August 16, 2025 |
| 72162-2135-2 | 72162-2135 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2135-2) / 20 g in 1 TUBE | June 15, 2017 |
| 72162-2135-4 | 72162-2135 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2135-4) / 45 g in 1 TUBE | June 15, 2017 |
| 72162-2158-2 | 72162-2158 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2158-2) / 45 g in 1 TUBE | December 7, 2023 |
| 21922-077-06 | 21922-077 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-077-06) / 45 g in 1 TUBE | February 13, 2026 |
| 21922-077-25 | 21922-077 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-077-25) / 20 g in 1 TUBE | February 13, 2026 |
| 21922-078-06 | 21922-078 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-078-06) / 45 g in 1 TUBE | March 26, 2026 |
| 21922-078-25 | 21922-078 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-078-25) / 20 g in 1 TUBE | March 26, 2026 |
| 21922-079-06 | 21922-079 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-079-06) / 45 g in 1 TUBE | July 11, 2025 |
| 21922-079-25 | 21922-079 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-079-25) / 20 g in 1 TUBE | July 11, 2025 |
| 0378-8082-20 | 0378-8082 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (0378-8082-20) / 20 g in 1 TUBE | April 29, 2019 |
| 0378-8082-45 | 0378-8082 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (0378-8082-45) / 45 g in 1 TUBE | April 3, 2019 |
| 0378-8083-20 | 0378-8083 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (0378-8083-20) / 20 g in 1 TUBE | July 12, 2019 |
| 0378-8083-45 | 0378-8083 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (0378-8083-45) / 45 g in 1 TUBE | December 17, 2018 |
| 0378-8084-20 | 0378-8084 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (0378-8084-20) / 20 g in 1 TUBE | July 25, 2019 |
| 0378-8084-45 | 0378-8084 | Mylan Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (0378-8084-45) / 45 g in 1 TUBE | February 27, 2019 |
| 16714-249-01 | 16714-249 | NORTHSTAR RX LLC | 1 TUBE in 1 CARTON (16714-249-01) / 20 g in 1 TUBE | February 25, 2022 |
| 16714-249-02 | 16714-249 | NORTHSTAR RX LLC | 1 TUBE in 1 CARTON (16714-249-02) / 45 g in 1 TUBE | February 25, 2022 |
| 16714-250-01 | 16714-250 | NORTHSTAR RX LLC | 1 TUBE in 1 CARTON (16714-250-01) / 20 g in 1 TUBE | February 25, 2022 |
| 16714-250-02 | 16714-250 | NORTHSTAR RX LLC | 1 TUBE in 1 CARTON (16714-250-02) / 45 g in 1 TUBE | February 25, 2022 |
| 16714-270-01 | 16714-270 | NORTHSTAR RX LLC | 1 TUBE in 1 CARTON (16714-270-01) / 20 g in 1 TUBE | January 5, 2023 |
| 16714-270-02 | 16714-270 | NORTHSTAR RX LLC | 1 TUBE in 1 CARTON (16714-270-02) / 45 g in 1 TUBE | January 5, 2023 |
| 68071-3825-2 | 68071-3825 | NuCare Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68071-3825-2) / 20 g in 1 TUBE | April 2, 2025 |
| 68071-3826-2 | 68071-3826 | NuCare Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68071-3826-2) / 20 g in 1 TUBE | April 2, 2025 |
| 68071-3865-2 | 68071-3865 | NuCare Pharmaceuticals,Inc. | 1 TUBE in 1 CARTON (68071-3865-2) / 20 g in 1 TUBE | June 10, 2025 |
| 68071-3888-2 | 68071-3888 | NuCare Pharmaceuticals,Inc. | 1 TUBE in 1 CARTON (68071-3888-2) / 20 g in 1 TUBE | September 3, 2025 |
| 68071-3889-2 | 68071-3889 | NuCare Pharmaceuticals,Inc. | 1 TUBE in 1 CARTON (68071-3889-2) / 20 g in 1 TUBE | September 3, 2025 |
| 68071-3945-2 | 68071-3945 | NuCare Pharmaceuticals,Inc. | 1 TUBE in 1 CARTON (68071-3945-2) / 20 g in 1 TUBE | January 9, 2026 |
| 0574-2201-20 | 0574-2201 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2201-20) / 20 g in 1 TUBE | March 30, 2017 |
| 0574-2201-45 | 0574-2201 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2201-45) / 45 g in 1 TUBE | April 17, 2017 |
| 0574-2205-20 | 0574-2205 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2205-20) / 20 g in 1 TUBE | May 5, 2017 |
| 0574-2205-45 | 0574-2205 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2205-45) / 45 g in 1 TUBE | April 26, 2017 |
| 0574-2225-20 | 0574-2225 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2225-20) / 20 g in 1 TUBE | June 15, 2017 |
| 0574-2225-45 | 0574-2225 | Padagis US LLC | 1 TUBE in 1 CARTON (0574-2225-45) / 45 g in 1 TUBE | June 15, 2017 |
| 68788-4069-2 | 68788-4069 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-4069-2) / 20 g in 1 TUBE | January 28, 2026 |
| 68788-8857-2 | 68788-8857 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8857-2) / 20 g in 1 TUBE | April 11, 2025 |
| 70518-3233-0 | 70518-3233 | REMEDYREPACK INC. | 1 TUBE in 1 CARTON (70518-3233-0) / 20 g in 1 TUBE | October 11, 2021 |
| 67296-2287-4 | 67296-2287 | Redpharm Drug | 1 TUBE in 1 CARTON (67296-2287-4) / 45 g in 1 TUBE | January 5, 2023 |
| 51672-1394-0 | 51672-1394 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1394-0) / 20 g in 1 TUBE | January 25, 2019 |
| 51672-1394-9 | 51672-1394 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1394-9) / 45 g in 1 TUBE | January 25, 2019 |
| 51672-1395-0 | 51672-1395 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1395-0) / 20 g in 1 TUBE | January 22, 2019 |
| 51672-1395-9 | 51672-1395 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1395-9) / 45 g in 1 TUBE | January 22, 2019 |
| 51672-1407-0 | 51672-1407 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1407-0) / 20 g in 1 TUBE | January 5, 2023 |
| 51672-1407-9 | 51672-1407 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1407-9) / 45 g in 1 TUBE | January 5, 2023 |
| 72578-153-08 | 72578-153 | Viona Pharmaceuticals Inc | 1 TUBE in 1 CARTON (72578-153-08) / 45 g in 1 TUBE | April 30, 2024 |
| 72578-153-09 | 72578-153 | Viona Pharmaceuticals Inc | 1 TUBE in 1 CARTON (72578-153-09) / 20 g in 1 TUBE | April 30, 2024 |
| 70771-1873-2 | 70771-1873 | Zydus Lifesciences Limited | 1 TUBE in 1 CARTON (70771-1873-2) / 20 g in 1 TUBE | April 30, 2024 |
| 70771-1873-4 | 70771-1873 | Zydus Lifesciences Limited | 1 TUBE in 1 CARTON (70771-1873-4) / 45 g in 1 TUBE | April 30, 2024 |
| 50090-0651 | 50090-0651 | A-S Medication Solutions | — | April 20, 1998 |
| 50090-3058 | 50090-3058 | A-S Medication Solutions | — | April 26, 2017 |
| 50090-3128 | 50090-3128 | A-S Medication Solutions | — | June 15, 2017 |
| 50090-4347 | 50090-4347 | A-S Medication Solutions | — | January 22, 2019 |
| 50090-6819 | 50090-6819 | A-S Medication Solutions | — | January 25, 2019 |
| 50090-7171 | 50090-7171 | A-S Medication Solutions | — | January 5, 2023 |
| 0472-0117 | 0472-0117 | Actavis Pharma, Inc. | — | April 20, 1998 |
| 62332-807 | 62332-807 | Alembic Pharmaceuticals Inc. | — | May 1, 2024 |
| 62332-808 | 62332-808 | Alembic Pharmaceuticals Inc. | — | June 11, 2026 |
| 62332-809 | 62332-809 | Alembic Pharmaceuticals Inc. | — | August 16, 2025 |
| 46708-807 | 46708-807 | Alembic Pharmaceuticals Limited | — | April 25, 2025 |
| 46708-808 | 46708-808 | Alembic Pharmaceuticals Limited | — | June 11, 2026 |
| 46708-809 | 46708-809 | Alembic Pharmaceuticals Limited | — | August 16, 2025 |
| 72162-2135 | 72162-2135 | Bryant Ranch Prepack | — | June 15, 2017 |
| 72162-2158 | 72162-2158 | Bryant Ranch Prepack | — | April 26, 2017 |
| 21922-077 | 21922-077 | Encube Ethicals, Inc. | — | February 13, 2026 |
| 21922-078 | 21922-078 | Encube Ethicals, Inc. | — | March 26, 2026 |
| 21922-079 | 21922-079 | Encube Ethicals, Inc. | — | July 11, 2025 |
| 0378-8082 | 0378-8082 | Mylan Pharmaceuticals Inc. | — | April 3, 2019 |
| 0378-8083 | 0378-8083 | Mylan Pharmaceuticals Inc. | — | November 5, 2018 |
| 0378-8084 | 0378-8084 | Mylan Pharmaceuticals Inc. | — | February 27, 2019 |
| 16714-249 | 16714-249 | NORTHSTAR RX LLC | — | January 25, 2019 |
| 16714-250 | 16714-250 | NORTHSTAR RX LLC | — | January 22, 2019 |
| 16714-270 | 16714-270 | NORTHSTAR RX LLC | — | January 5, 2023 |
| 68071-3825 | 68071-3825 | NuCare Pharmaceuticals, Inc. | — | January 5, 2023 |
| 68071-3826 | 68071-3826 | NuCare Pharmaceuticals, Inc. | — | January 22, 2019 |
| 68071-3865 | 68071-3865 | NuCare Pharmaceuticals,Inc. | — | January 25, 2019 |
| 68071-3888 | 68071-3888 | NuCare Pharmaceuticals,Inc. | — | January 5, 2023 |
| 68071-3889 | 68071-3889 | NuCare Pharmaceuticals,Inc. | — | January 22, 2019 |
| 68071-3945 | 68071-3945 | NuCare Pharmaceuticals,Inc. | — | June 15, 2017 |
| 0574-2201 | 0574-2201 | Padagis US LLC | — | March 30, 2017 |
| 0574-2205 | 0574-2205 | Padagis US LLC | — | April 26, 2017 |
| 0574-2225 | 0574-2225 | Padagis US LLC | — | June 15, 2017 |
| 68788-4069 | 68788-4069 | Preferred Pharmaceuticals Inc. | — | January 28, 2026 |
| 68788-8857 | 68788-8857 | Preferred Pharmaceuticals Inc. | — | April 11, 2025 |
| 70518-3233 | 70518-3233 | REMEDYREPACK INC. | — | October 11, 2021 |
| 67296-2287 | 67296-2287 | Redpharm Drug | — | January 5, 2023 |
| 51672-1394 | 51672-1394 | Sun Pharmaceutical Industries, Inc. | — | January 25, 2019 |
| 51672-1395 | 51672-1395 | Sun Pharmaceutical Industries, Inc. | — | January 22, 2019 |
| 51672-1407 | 51672-1407 | Sun Pharmaceutical Industries, Inc. | — | January 5, 2023 |
| 72578-153 | 72578-153 | Viona Pharmaceuticals Inc | — | April 30, 2024 |
| 70771-1873 | 70771-1873 | Zydus Lifesciences Limited | — | April 30, 2024 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.